NCT00678782View on ClinicalTrials.gov

Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Persistent Knee Joint Synovitis
Interventions
DRUG

etanercept

etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period

DRUG

placebo

Placebo (NaCl) 0.5 ml intraarticular injection

Trial Locations (1)

35128

Centro Multidisciplinare di Day Surgery, Azienda Ospedaliera di Padova, Ospedale Busonera, via Gattamelata 64, Padua

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Azienda Ospedaliera di Padova

OTHER

lead

University of Padova

OTHER

NCT00678782 - Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis | Biotech Hunter | Biotech Hunter